Journal Title
Title of Journal: Cardiovasc Drugs Ther
|
Abbravation: Cardiovascular Drugs and Therapy
|
|
|
|
|
|
|
|
Authors: Yuya Matsue Makoto Suzuki Wataru Nagahori Kazuki Yoshida Yuko Onishi Yasuhiro Satoh Yuichi Ono Toshihiko Nishioka Makoto Noda Kaoru Sugi Sho Torii Tamotsu Tejima Harumizu Sakurada Satoshi Yamaguchi Kaoru Okishige Hiroyuki Fujii Atsushi Takahashi
Publish Date: 2013/09/19
Volume: 28, Issue: 1, Pages: 73-77
Abstract
Over half of all admitted acute decompensated heart failure ADHF patients have renal failure Although diuretics represent the mainstay of treatment strategy even in this population there are unmet needs for safer and more effective treatment Tolvaptan is a vasopressin2 receptor antagonist and we hypothesized that adding tolvaptan to standard diuretic therapy would be more effective in ADHF patients with renal function impairmentThe Answering question on tolvaptan’s efficacy for patients with acute decompensated heart failure and renal failure AQUAMARINE is a multicenter randomized controlled clinical trial which will enroll 220 patients from 17 hospitals in Japan ADHF patients whose estimated glomerular filtration rate is above 15 and below 60 mL/min/172 m2 will be randomly assigned within 6 h after admission to usual care with furosemide or tolvaptan addon therapy Primary endpoint is achieved urine output within 48 h Secondary endpoints include dyspnea relief measured by 7points Likert scale incidence of worsening renal function dose of furosemide used within 48 h and changes of brain natriuretic peptideThis study is the first multicenter study in Japan to evaluate clinical effectiveness of tolvaptan addon therapy in ADHF patients with renal failure The results of this study address the treatment strategy of this highrisk population UMIN Clinical Trial Registry Number UMIN000007109
Keywords:
.
|
Other Papers In This Journal:
|